Pfizer Inc. and India's Ranbaxy Laboratories Ltd. said June 18 they have settled their patent dispute over the blockbuster cholesterol drug Lipitor, delaying the release of generic versions in the U.S. until Nov. 30, 2011. Under terms of the deal, Ranbaxy also will be able to sell generic versions of Lipitor in Canada, Belgium, the Netherlands, Germany, Sweden, Italy and Australia. Pfizer and Ranbaxy also have resolved their disputes regarding Lipitor in Malaysia, Brunei, Peru and Vietnam, and regarding hypertension drug Accupril in the U.S. and Viagra in Ecuador.
June 18, 2008 at 05:05 AM
1 minute read
The original version of this story was published on Law.Com
Pfizer Inc. and India’s Ranbaxy Laboratories Ltd. said June 18 they have settled their patent dispute over the blockbuster cholesterol drug Lipitor, delaying the release of generic versions in the U.S. until Nov. 30, 2011.
Pfizer’s Lipitor is the world’s best-selling drug, generating nearly $13 billion in 2007 sales.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
